Novartis conducts safety study of Iptacopan in PNH patients using registry data
Novartis is conducting a post-authorization safety study of Iptacopan in adult PNH patients using data from the IPIG PNH registry.
Therapeutic Area
Therapeutic area intelligence for Paroxysmal Nocturnal Hemoglobinuria with 1 indexed intelligence signal across regulatory, clinical, competitive, and market developments.
No catalysts indexed for this entity yet.
No related entities indexed yet.
Newsletter
Concise strategic intelligence on regulatory, clinical, competitive, and market developments — free to subscribe.
No paywall. No spam. Unsubscribe anytime.